Malignant Peritoneal Mesothelioma and Hydrosalpinx: A Case Report and Literature Review

doi:10.12280/gjszjk.20220580

Abstract

Abstract:

Malignant peritoneal mesothelioma is a rare and extremely malignant tumor. It is difficult for clinicians to diagnose early for its insidious onset and lack of specific clinical manifestations, laboratory indicators and imaging characteristics. At present, the accurate diagnosis dependes on the pathological examination and immunochemistry. In this paper, we report a case of malignant peritoneal mesothelioma found by the laparoscopic surgery due to "hydrofallopian tube". This is a female patient of childbearing age who had primary infertility for 3 years. The patient had no history of asbestos exposure, unclear etiology, atypical clinical manifestations. The diagnosis of malignant peritoneal mesothelioma was very difficult before histopathological examination. We analyze retrospectively the medical records of the patient and review of the previous literature. We explore the etiology, diagnosis and treatment of malignant peritoneal mesothelioma and enhance clinicians′ comprehension.

Key words: Mesothelioma, malignant, Immunohistochemistry, Case reports, Malignant peritoneal mesothelioma

HUANG Qiu-fang, LU Guang-mei, LIU Bao-qin, LI Ming-luan, ZHANG Yi. Malignant Peritoneal Mesothelioma and Hydrosalpinx: A Case Report and Literature Review[J]. Journal of International Reproductive Health/Family Planning, 2023, 42(4): 296-300.

Figures/Tables 3

References 30

[1]	Kaya H, Sezgı C, Tanrıkulu AC, et al. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma[J]. Neoplasma, 2014, 61(4):433-438. doi: 10.4149/neo_2014_053. doi: 10.4149/neo_2014_053 pmid: 24645844
[2]	马建婷, 傅云雀, 杨春林, 等. 女性恶性腹膜间皮瘤52例预后因素分析[J]. 中国现代医生, 2020, 58(23):75-79.
[3]	Sharma H, Bell I, Schofield J, et al. Primary peritoneal mesothelioma: case series and literature review[J]. Clin Res Hepatol Gastroenterol, 2011, 35(1):55-59. doi: 10.1016/j.gcb.2010.07.016. doi: 10.1016/j.gcb.2010.07.016 URL
[4]	Kusamura S, Kepenekian V, Villeneuve L, et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up[J]. Eur J Surg Oncol, 2021, 47(1):36-59. doi: 10.1016/j.ejso.2020.02.011. doi: 10.1016/j.ejso.2020.02.011 pmid: 32209311
[5]	Miller J, William H. A malignant tumour arising from the endothelium of the peritoneum, and producing a mucoid ascitic fluid[J]. J Pathol Bacteriol, 1908, 12(2):267-278. doi: 10.1002/(ISSN)1555-2039 URL
[6]	李智宇, 崔修铮, 邵永孚, 等. 恶性腹膜间皮瘤的诊治体会[J]. 中国肿瘤临床, 2007, 34(23):1365-1367. doi: 10.3969/j.issn.1000-8179.2007.23.014. doi: 10.3969/j.issn.1000-8179.2007.23.014
[7]	邵华江, 马建婷, 杨秀儿, 等. 女性腹膜恶性间皮瘤26例诊治体会[C]. 2013年浙江省妇科肿瘤学术年会暨省级医学继续教育项目“宫颈癌筛查及子宫颈疾病规范化诊治”学习班资料汇编, 2013:124-125.
[8]	曾然, 刘芳, 杨锦, 等. 晚期恶性胸膜间皮瘤免疫治疗进展[J]. 中华转移性肿瘤杂志, 2022, 5(1):96-100. doi: 10.3760/cma.j.cn101548-20210524-00059. doi: 10.3760/cma.j.cn101548-20210524-00059
[9]	沈蔚, 刘佳琪, 陈俊斐, 等. 恶性间皮瘤36例患者生存分析[J]. 预防医学, 2022, 34(1):66-69. doi: 10.19485/j.cnki.issn2096-5087.2022.01.014. doi: 10.19485/j.cnki.issn2096-5087.2022.01.014
[10]	林嘉恒, 劳学军. 升结肠恶性腹膜间皮瘤一例[J]. 海南医学, 2022, 33(7):947-948. doi: 10.3969/j.issn.1003-6350.2022.07.033. doi: 10.3969/j.issn.1003-6350.2022.07.033
[11]	席娟, 郝娟, 陈嘉屿. 腹膜恶性间皮瘤的研究进展[J]. 当代医学, 2020, 26(25):192-194. doi: 10.3969/j.issn.1009-4393.2020.25.084. doi: 10.3969/j.issn.1009-4393.2020.25.084
[12]	曹泽毅. 中华妇产科学(下册)[M]. 2版. 北京: 人民卫生出版社, 2008:2240-2244.
[13]	孙艳梅, 冯大宁. 腹膜恶性间皮瘤合并子宫肌瘤1例[J]. 实用医学杂志, 2007, 23(19):3059. doi: 10.3969/j.issn.1006-5725.2007.19.091. doi: 10.3969/j.issn.1006-5725.2007.19.091
[14]	桑倩, 张国俊. 恶性胸膜间皮瘤诊治进展[J]. 肿瘤基础与临床, 2016, 29(3):274-277. doi: 10.3969/j.issn.1673-5412.2016.03.029. doi: 10.3969/j.issn.1673-5412.2016.03.029
[15]	李智昊, 呼群. 关于恶性胸膜间皮瘤的病因和内科治疗的简述[J]. 中国医学创新, 2019, 16(11):163-168. doi: 10.3969/j.issn.1674-4985.2019.11.044. doi: 10.3969/j.issn.1674-4985.2019.11.044
[16]	Bridda A, Padoan I, Mencarelli R, et al. Peritoneal mesothelioma: a review[J]. Med Gen Med, 2007, 9(2):32.
[17]	Cao S, Jin S, Cao J, et al. Advances in malignant peritoneal mesothelioma[J]. Int J Colorectal Dis, 2015, 30(1):1-10. doi: 10.1007/s00384-014-2029-1. doi: 10.1007/s00384-014-2029-1 pmid: 25331029
[18]	Gazdar AF, Carbone M. Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40[J]. Clin Lung Cancer, 2003, 5(3):177-181. doi: 10.3816/CLC.2003.n.031. doi: 10.3816/CLC.2003.n.031 pmid: 14667274
[19]	中国抗癌协会腹膜肿瘤专业委员会, 中国抗癌协会肿瘤热疗专业委员会, 北京癌症防治学会肿瘤热疗专业委员会. 弥漫性恶性腹膜间皮瘤诊治中国专家共识[J]. 中华医学杂志, 2021, 101(36):2839-2849. doi: 10.3760/cma.j.cn112137-20210210-00405. doi: 10.3760/cma.j.cn112137-20210210-00405
[20]	魏思忱, 郑国启, 白文元. 恶性腹膜间皮瘤的研究进展[J]. 中华消化杂志, 2014, 34(3):212-214. doi: 10.3760/cma.j.issn.0254-1432.2014.03.026. doi: 10.3760/cma.j.issn.0254-1432.2014.03.026
[21]	陈凯燕, 郭振英, 苏丹, 等. 恶性间皮瘤在中国的发病及诊治现状分析[J]. 中华胸心血管外科杂志, 2017, 33(7):443-446. doi: 10.3760/cma.j.issn.1001-4497.2017.07.018. doi: 10.3760/cma.j.issn.1001-4497.2017.07.018
[22]	Kawai T, Tominaga S, Hiroi S, et al. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses[J]. J Clin Pathol, 2016, 69(8):706-712. doi: 10.1136/jclinpath-2015-203211. doi: 10.1136/jclinpath-2015-203211 pmid: 26729015
[23]	杜雪梅, 昌红, 李雁. 恶性腹膜间皮瘤临床病理进展[J]. 临床与实验病理学杂志, 2021, 37(4):441-445. doi: 10.13315/j.cnki.cjcep.2021.04.014. doi: 10.13315/j.cnki.cjcep.2021.04.014
[24]	Tohumcuoğlu M, Büyükşimşek M, Kara İO, et al. The prognostic analysis of the some clinicopathological parameters and gene protein expressions in malignant mesothelioma[J]. Tuberk Toraks, 2019, 67(3):162-168. doi: 10.5578/tt.68517. doi: 10.5578/tt.68517 URL
[25]	Carbone M, Adusumilli PS, Alexander HR Jr, et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy[J]. CA Cancer J Clin, 2019, 69(5):402-429. doi: 10.3322/caac.21572. doi: 10.3322/caac.21572 URL
[26]	Boussios S, Moschetta M, Karathanasi A, et al. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives[J]. Ann Gastroenterol, 2018, 31(6):659-669. doi: 10.20524/aog.2018.0305. doi: 10.20524/aog.2018.0305
[27]	Deraco M, Cabras A, Baratti D, et al. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray[J]. Ann Surg Oncol, 2015, 22(13):4344-4351. doi: 10.1245/s10434-015-4498-z. doi: 10.1245/s10434-015-4498-z pmid: 25777091
[28]	王敏, 马帅, 赵柘, 等. 卵巢上皮样恶性间皮瘤一例并文献复习[J]. 国际生殖健康/计划生育杂志, 2019, 38(5):438-440. doi: 10.3969/j.issn.1674-1889.2019.05.019. doi: 10.3969/j.issn.1674-1889.2019.05.019
[29]	潘丹. 老年恶性腹膜间皮瘤的临床病理特征及预后因素分析[D]. 沈阳: 中国医科大学, 2021.
[30]	刘晨曦, 刘宝瑞, 沈洁. 携带FGFR2-GOLGA2融合基因恶性腹膜间皮瘤患者仑伐替尼治疗有效1例[J]. 临床肿瘤学杂志, 2022, 27(8):764-765. doi: 10.3969/j.issn.1009-0460.2022.08.015. doi: 10.3969/j.issn.1009-0460.2022.08.015